AI assistant
Emergent BioSolutions Inc. — Director's Dealing 2025
Dec 10, 2025
32870_dirs_2025-12-09_adf86048-6004-471f-9177-edfd8ab881bb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2025-12-05
Reporting Person: Richard Ronald (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-05 | Common Stock | S | 7100 | $12.1113 | Disposed | 98417 | Direct |
| 2025-12-05 | Common Stock | M | 25748 | $5.02 | Acquired | 124165 | Direct |
| 2025-12-05 | Common Stock | F | 10864 | $11.8978 | Disposed | 113301 | Direct |
| 2025-12-05 | Common Stock | S | 14884 | $11.8978 | Disposed | 98417 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-05 | Stock Option (Right to Buy) | $5.02 | M | 25748 | Disposed | 2031-05-22 | Common Stock (25748) | Direct |
Footnotes
F1: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.
F2: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12.
F3: Represents shares of common stock sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise.
F4: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97.
F5: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, as compensation for Board and Committee service. The shares underlying the options exercised were fully vested on May 22, 2025.